TG
BLCM

TLP Group’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

TLP Group’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-560
Closed -$111K – 399
2016
Q3 		$111K Buy
+560
New +$96.4K 0.12% 208

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

TLP Group's BLCM Position: Q4 2016 in Review

TLP Group sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q4 2016, closing a stake of 560 shares — an estimated $111K sold.

TLP Group first reported a position in BLCM in Q3 2016 and held it in 1 quarter. The position peaked at $111K in Q3 2016. 80 funds tracked by Wall St. Rank hold BLCM as of Q4 2016.

  • TLP Group reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
  • TLP Group sold 560 Bellicum Pharmaceuticals, Inc. shares in Q4 2016, an estimated $111K.
  • TLP Group first reported a position in Bellicum Pharmaceuticals, Inc. in Q3 2016 and held it in 1 quarter.
  • TLP Group's Bellicum Pharmaceuticals, Inc. position peaked at $111K in Q3 2016.
  • 80 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q4 2016.

Based on TLP Group's 13F filing for Q4 2016, filed 2 Feb 2017.